As of October 27, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Krystal Biotech, Inc. (the "Company"). The largest reported stake is Krish S. Krishnan's, at 11.5%. 3 filings are on record since March 27, 2026 (Schedule 13G/A, May 4, 2026).
Sell to companies like Krystal Biotech, Inc. (the "Company")? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Krish S. Krishnan · Percent: 11.5% · SCHEDULE 13G/A
- · Holder: Vanguard Portfolio Management · Percent: 5.05% · SCHEDULE 13G
- · Holder: The Vanguard Group · Percent: 0% · SCHEDULE 13G/A
Krystal Biotech, Inc. (the "Company") has 3 Schedule 13D or 13G filings on record since 2026-03-27. 2 holders' latest filing reports 5% or more of common stock, $0.00001 par value ("common stock"). Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 11.5% | 3,388,283 | SCHEDULE 13G/A, 2026-05-04 | 2026-03-31 | |
| Vanguard Portfolio Management | 5.05% | 1,479,111 | SCHEDULE 13G, 2026-04-29 | 2026-03-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Holding shares or following this stake? See who's behind Krystal Biotech, Inc. (the "Company") and the warning signs.
Free to see. No signup.
Watch Krystal Biotech, Inc. (the "Company")
Get an email when Krystal Biotech, Inc. (the "Company") files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Krystal Biotech, Inc. (the "Company")?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Krystal Biotech, Inc. (the "Company"): verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Krystal Biotech, Inc. (the "Company") covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-29 | Vanguard Portfolio Management | 5.05% | SCHEDULE 13G |
| 2026-05-04 | Krish S. Krishnan | 11.5% | SCHEDULE 13G/A |
Questions about who owns Krystal Biotech, Inc. (the "Company")
Who owns Krystal Biotech, Inc. (the "Company")?
On this page, 2 holders' latest ownership filings report 5% or more of Krystal Biotech, Inc. (the "Company"): Krish S. Krishnan (11.5%, Schedule 13G/A, filed 2026-05-04) and Vanguard Portfolio Management (5.05%, Schedule 13G, filed 2026-04-29).
Who are the largest shareholders of Krystal Biotech, Inc. (the "Company")?
By the share each holder's latest filing reports, the largest holders of Krystal Biotech, Inc. (the "Company") on this page are Krish S. Krishnan (11.5%) and Vanguard Portfolio Management (5.05%).
When did Krish S. Krishnan buy into Krystal Biotech, Inc. (the "Company")?
The filings give report dates, not purchase dates. The earliest filing from Krish S. Krishnan on this page is the Schedule 13G/A, filed 2026-05-04, reporting 11.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 3 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Krystal Biotech, Inc. (the "Company"). With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.